GYNECOLOGY

23: The impact of life-long maternal HIV infection on pregnancy outcomes in women delivering in south carolina

May 2, 2017 by in GYNECOLOGY Comments Off on 23: The impact of life-long maternal HIV infection on pregnancy outcomes in women delivering in south carolina

Objectives Our objective was to evaluate HIV RNA virologic suppression and pregnancy outcomes for women with perinatally acquired HIV infection (PHIV) compared to women with non-perinatal HIV (nPHIV) infection over…

read more

20: Retrospective review of maternal and neonatal outcomes with discordant histologic and clinical chorioamnionitis in labor

May 2, 2017 by in GYNECOLOGY Comments Off on 20: Retrospective review of maternal and neonatal outcomes with discordant histologic and clinical chorioamnionitis in labor

Objectives The clinical diagnosis of chorioamnionitis requires a high index of suspicion. Unrecognized and untreated chorioamnionitis can lead to poor maternal and neonatal outcomes. Recent study of the concordance between…

read more

16: A phase 3 randomized, double-blind, placebo-controlled study to confirm the efficacy and safety of a single, oral dose of SYM-1219, a granule formulation containing 2 grams of secnidazole, for the treatment of bacterial vaginosis

May 2, 2017 by in GYNECOLOGY Comments Off on 16: A phase 3 randomized, double-blind, placebo-controlled study to confirm the efficacy and safety of a single, oral dose of SYM-1219, a granule formulation containing 2 grams of secnidazole, for the treatment of bacterial vaginosis

Objectives SYM-1219, a granule formulation of secnidazole, is being developed as a single oral dose therapy for bacterial vaginosis (BV). A previous study of SYM-1219 for the treatment of BV…

read more

15: To evaluate the efficacy and safety of VT-1161, a potent, highly selective inhibitor of fungal CYP51, in treating women with a documented history of recurrent vulvovaginal candidiasis (RVVC)

May 2, 2017 by in GYNECOLOGY Comments Off on 15: To evaluate the efficacy and safety of VT-1161, a potent, highly selective inhibitor of fungal CYP51, in treating women with a documented history of recurrent vulvovaginal candidiasis (RVVC)

Objectives To evaluate the efficacy and safety of VT-1161, a potent, highly selective inhibitor of fungal CYP51, in treating women with a documented history of recurrent vulvovaginal candidiasis (RVVC). Methods…

read more
Get Clinical Tree app for offline access